Calidi Biotherapeutics to Present at H.C. Wainwright Conference
Event summary
- Calidi Biotherapeutics (NYSE American: CLDI) will participate in the H.C. Wainwright 28th Annual Global Investment Conference from September 14–16, 2026.
- CEO Eric Poma, Ph.D., will hold one-on-one investor meetings during the event.
- A virtual presentation will be available on-demand starting September 11, 2026.
- CLD-401, the lead candidate from the RedTail platform, is in IND-enabling studies for metastatic non-small cell lung cancer and head and neck cancer.
The big picture
Calidi Biotherapeutics is positioning itself as a leader in targeted genetic medicines, leveraging its RedTail platform to address high-unmet medical needs in oncology. The company’s participation in the H.C. Wainwright conference underscores its focus on engaging investors as it advances its pipeline. Success in this space hinges on both scientific breakthroughs and market adoption of its novel approach to virotherapy.
What we're watching
- Pipeline Progress
- The pace at which CLD-401 advances through IND-enabling studies will determine Calidi’s near-term valuation.
- Investor Sentiment
- How investor meetings at the conference impact CLDI’s stock performance in the following weeks.
- Platform Expansion
- Whether Calidi can sustain momentum in developing additional therapies using the RedTail platform.
Related topics